150 related articles for article (PubMed ID: 38430119)
1. Second-line immunotherapy in new onset refractory status epilepticus.
Hanin A; Muscal E; Hirsch LJ
Epilepsia; 2024 May; 65(5):1203-1223. PubMed ID: 38430119
[TBL] [Abstract][Full Text] [Related]
2. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): Effectiveness and safety from a case-series.
Aledo-Serrano A; Hariramani R; Gonzalez-Martinez A; Álvarez-Troncoso J; Toledano R; Bayat A; Garcia-Morales I; Becerra JL; Villegas-Martínez I; Beltran-Corbellini A; Gil-Nagel A
Seizure; 2022 Aug; 100():51-55. PubMed ID: 35759951
[TBL] [Abstract][Full Text] [Related]
3. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome.
Sheikh Z; Hirsch LJ
Front Neurol; 2023; 14():1150496. PubMed ID: 37251223
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.
Cantarín-Extremera V; Jiménez-Legido M; Duat-Rodríguez A; García-Fernández M; Ortiz-Cabrera NV; Ruiz-Falcó-Rojas ML; González-Gutiérrez-Solana L
J Neuroimmunol; 2020 Mar; 340():577142. PubMed ID: 31935626
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab treatment for new onset refractory status epilepticus.
Jun JS; Lee ST; Kim R; Chu K; Lee SK
Ann Neurol; 2018 Dec; 84(6):940-945. PubMed ID: 30408233
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort).
Sculier C; Barcia Aguilar C; Gaspard N; Gaínza-Lein M; Sánchez Fernández I; Amengual-Gual M; Anderson A; Arya R; Burrows BT; Brenton JN; Carpenter JL; Chapman KE; Clark J; Gaillard WD; Glauser TA; Goldstein JL; Goodkin HP; Gorman M; Lai YC; McDonough TL; Mikati MA; Nayak A; Peariso K; Riviello J; Rusie A; Sperberg K; Stredny CM; Tasker RC; Tchapyjnikov D; Vasquez A; Wainwright MS; Wilfong AA; Williams K; Loddenkemper T;
Epilepsia; 2021 Jul; 62(7):1629-1642. PubMed ID: 34091885
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis.
Jimenez AD; Gopaul M; Asbell H; Aydemir S; Basha MM; Batra A; Damien C; Day GS; Eka O; Eschbach K; Fatima S; Fields MC; Foreman B; Gerard EE; Gofton TE; Haider HA; Hantus ST; Hocker S; Jongeling A; Kalkach Aparicio M; Kandula P; Kang P; Kazazian K; Kellogg MA; Kim M; Lee JW; Marcuse LV; McGraw CM; Mohamed W; Orozco J; Pimentel C; Punia V; Ramirez AM; Steriade C; Struck AF; Taraschenko O; Treister AK; Yoo JY; Zafar S; Zhou DJ; Zutshi D; Gaspard N; Hirsch LJ; Hanin A
Epilepsia; 2024 Jun; 65(6):e87-e96. PubMed ID: 38625055
[TBL] [Abstract][Full Text] [Related]
8. Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment.
Wadayama T; Shimizu M; Yata T; Ishikura T; Kajiyama Y; Hirozawa D; Okuno T; Mochizuki H
J Neuroimmunol; 2022 Feb; 363():577789. PubMed ID: 34973472
[TBL] [Abstract][Full Text] [Related]
9. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult.
Girardin ML; Flamand T; Roignot O; Abi Warde MT; Mutschler V; Voulleminot P; Guillot M; Dinkelacker V; De Saint-Martin A
Epilepsia; 2023 Jun; 64(6):e87-e92. PubMed ID: 36961094
[TBL] [Abstract][Full Text] [Related]
10. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.
Hirsch LJ; Gaspard N; van Baalen A; Nabbout R; Demeret S; Loddenkemper T; Navarro V; Specchio N; Lagae L; Rossetti AO; Hocker S; Gofton TE; Abend NS; Gilmore EJ; Hahn C; Khosravani H; Rosenow F; Trinka E
Epilepsia; 2018 Apr; 59(4):739-744. PubMed ID: 29399791
[TBL] [Abstract][Full Text] [Related]
11. Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis.
Hanin A; Jimenez AD; Gopaul M; Asbell H; Aydemir S; Basha MM; Batra A; Damien C; Day GS; Eka O; Eschbach K; Fatima S; Fields MC; Foreman B; Gerard EE; Gofton TE; Haider HA; Hantus ST; Hocker S; Jongeling A; Kalkach Aparicio M; Kandula P; Kang P; Kazazian K; Kellogg MA; Kim M; Lee JW; Marcuse LV; McGraw CM; Mohamed W; Orozco J; Pimentel CM; Punia V; Ramirez AM; Steriade C; Struck AF; Taraschenko O; Treister AK; Wainwright MS; Yoo JY; Zafar S; Zhou DJ; Zutshi D; Gaspard N; Hirsch LJ
Epilepsia; 2024 Jun; ():. PubMed ID: 38837761
[TBL] [Abstract][Full Text] [Related]
12. New onset refractory status epilepticus (NORSE).
Sculier C; Gaspard N
Seizure; 2019 May; 68():72-78. PubMed ID: 30482654
[TBL] [Abstract][Full Text] [Related]
13. Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents.
Hon KL; Leung AKC; Torres AR
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):128-135. PubMed ID: 29745347
[TBL] [Abstract][Full Text] [Related]
14. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.
Gaspard N; Hirsch LJ; Sculier C; Loddenkemper T; van Baalen A; Lancrenon J; Emmery M; Specchio N; Farias-Moeller R; Wong N; Nabbout R
Epilepsia; 2018 Apr; 59(4):745-752. PubMed ID: 29476535
[TBL] [Abstract][Full Text] [Related]
15. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) of unknown aetiology: A comparison of the incomparable?
Nausch E; Schaffeldt L; Tautorat I; Margraf NG; Häusler M; Kluger G; Kellinghaus C; Borzikowsky C; Laufs H; van Baalen A
Seizure; 2022 Mar; 96():18-21. PubMed ID: 35042004
[TBL] [Abstract][Full Text] [Related]
16. Severe, Refractory Seizures: New-Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome.
Carson R; Stredny CM
Med Clin North Am; 2024 Jan; 108(1):201-213. PubMed ID: 37951651
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES).
Stredny CM; Case S; Sansevere AJ; Son M; Henderson L; Gorman MP
Child Neurol Open; 2020; 7():2329048X20979253. PubMed ID: 33403221
[TBL] [Abstract][Full Text] [Related]
18. The seasonality of new-onset refractory status epilepticus (NORSE).
Gopaul MT; Hanin A; Cespedes J; Pulluru Y; Kazazian K; van Baalen A; Gofton TE; Gaspard N; Hirsch LJ
Epilepsia; 2023 Jun; 64(6):e112-e117. PubMed ID: 37013696
[TBL] [Abstract][Full Text] [Related]
19. NORSE seasonality may vary geographically in adults.
Bolle AE; Gaist T; Kuljis AME; Blaabjerg M; Beier CP
Epilepsia Open; 2024 Jun; 9(3):1088-1095. PubMed ID: 38635008
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of 92 children with new-onset refractory status epilepticus.
Wu J; Lan X; Yan L; Hu Y; Hong S; Jiang L; Chen J
Epilepsy Behav; 2021 Dec; 125():108413. PubMed ID: 34794014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
